Regulatory milestones

Biogen Idec Inc. (NASDAQ:BIIB) was up $8.39 to $235.24 last week after submitting a BLA to FDA for Plegridy peginterferon beta-1a (BIIB017) to treat relapsing forms of multiple sclerosis (MS). The company said it expects to submit an MAA to EMA in the coming weeks.